Literature DB >> 10974366

Retroviral integrase inhibitors year 2000: update and perspectives.

Y Pommier1, C Marchand, N Neamati.   

Abstract

HIV-1 integrase is an essential enzyme for retroviral replication and a rational target for the design of anti-AIDS drugs. A number of inhibitors have been reported in the past 8 years. This review focuses on the recent developments in the past 2 years. There are now several inhibitors with known sites of actions and antiviral activity. The challenge is to convert these leads into drugs that will selectively target integrase in vivo, and can be added to our antiviral armamentarium.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10974366     DOI： 10.1016/s0166-3542(00)00112-1

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  14 in total

1.  Ring substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1.

Authors:  D Christopher Meadows; Tino Sanchez; Nouri Neamati; Thomas W North; Jacquelyn Gervay-Hague
Journal:  Bioorg Med Chem       Date:  2006-10-30       Impact factor: 3.641

2.  2D and 3D QSAR studies of diarylpyrimidine HIV-1 reverse transcriptase inhibitors.

Authors:  Joseph Rebehmed; Florent Barbault; Cátia Teixeira; François Maurel
Journal:  J Comput Aided Mol Des       Date:  2008-05-28       Impact factor: 3.686

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

4.  Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response.

Authors:  René Daniel; Gary Kao; Konstantin Taganov; James G Greger; Olga Favorova; George Merkel; Tim J Yen; Richard A Katz; Anna Marie Skalka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-04       Impact factor: 11.205

5.  Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction.

Authors:  Bénédicte Van Maele; Jan De Rijck; Erik De Clercq; Zeger Debyser
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups.

Authors:  Xing Fan; Feng-Hua Zhang; Rasha I Al-Safi; Li-Fan Zeng; Yumna Shabaik; Bikash Debnath; Tino W Sanchez; Srinivas Odde; Nouri Neamati; Ya-Qiu Long
Journal:  Bioorg Med Chem       Date:  2011-06-26       Impact factor: 3.641

7.  Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.

Authors:  Nick Shkriabai; Sachindra S Patil; Sonja Hess; Scott R Budihas; Robert Craigie; Terrence R Burke; Stuart F J Le Grice; Mamuka Kvaratskhelia
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

8.  Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA).

Authors:  Devendra K Dhaked; Jitender Verma; Anil Saran; Evans C Coutinho
Journal:  J Mol Model       Date:  2008-12-02       Impact factor: 1.810

9.  Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.

Authors:  Anneleen Hombrouck; Barbara Van Remoortel; Martine Michiels; Wim Noppe; Frauke Christ; Anders Eneroth; Britt Louise Sahlberg; Kurt Benkestock; Lotta Vrang; Nils Gunnar Johansson; Maria Letizia Barreca; Laura De Luca; Stefania Ferro; Alba Chimirri; Zeger Debyser; Myriam Witvrouw
Journal:  Antimicrob Agents Chemother       Date:  2008-06-09       Impact factor: 5.191

Review 10.  HIV-1 IN inhibitors: 2010 update and perspectives.

Authors:  Christophe Marchand; Kasthuraiah Maddali; Mathieu Métifiot; Yves Pommier
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.